Influence of polymorphisms in genes encoding immunoregulatory proteins and metabolizing enzymes on susceptibility and outcome in patients with diffuse large B-cell lymphoma treated with rituximab

Leukemia and Lymphoma

Volumn 54, Issue 10, 2013, Pages 2205-2214

  Yri, Olav E ^a,b   Ekstrom, Per Olaf ^a   Hilden, Vera ^a,c   Gaudernack, Gustav ^a   Liestol, Knut ^b,d   Smeland, Erlend B ^a,b   Holte, Harald ^b,e  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Faculty of Medicine   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

DLBCL; Polymorphisms; Prognosis; Risk; Rituximab

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOKINE; DOXORUBICIN; ETOPOSIDE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1; INTERLEUKIN 10; METHOTREXATE; PREDNISOLONE; RITUXIMAB; TROFOSFAMIDE; TUMOR NECROSIS FACTOR ALPHA; VINCRISTINE;

ADULT; AGED; ALLELE; ARTICLE; BLOOD DONOR; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; DRUG MEGADOSE; FEMALE; GENE DELETION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; IMMUNOREGULATION; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ALLELES; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; INTERLEUKIN-10; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, GENETIC; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84884476792     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.774392     Document Type: Article

References (53)

1. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.
2. Apredictive model for aggressive non-Hodgkin' s lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-994.
3. Forrest MS, Skibola CF, Lightfoot TJ, et al. Polymorphisms in innate immunity genes and risk of non-Hodgkin lymphoma. Br J Haematol 2006; 134: 180-183.
4. Kelly JL, Novak AJ, Fredericksen ZS, et al. Germline variation in apoptosis pathway genes and risk of non-Hodgkin's lymphoma. Cancer Epidemiol Biomarkers Prev 2010; 19: 2847-2858.
5. Cerhan JR, Novak AJ, Fredericksen ZS, et al. Risk of non-Hodgkin lymphoma in association with germline variation in complement genes. Br J Haematol 2009; 145: 614-623.
6. Ibrahim A, Rahman HA, Khorshied M, et al. Tumor necrosis factor alpha-308 and Lymphotoxin alpha + 252 genetic polymorphisms and the susceptibility to non-Hodgkin lymphoma in Egypt. Leuk Res 2012; 36: 694-698.
7. Wang SS, Cerhan JR, Hartge P, et al. Common genetic variants in proinfl ammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma. Cancer Res 2006; 66: 9771-9780.
8. Rothman N, Skibola CF, Wang SS, et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: A report from the InterLymph Consortium. Lancet Oncol 2006; 7: 27-38.
9. Skibola CF, Bracci PM, Nieters A, et al. Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium. Am J Epidemiol 2010; 171: 267-276.
10. Bel H Jr, Chatti A, Laatiri A, et al. Tumor necrosis factor promoter gene polymorphism associated with increased susceptibility to non-Hodgkin' s lymphomas. Eur J Haematol 2007; 78: 117-122.
11. Lan Q, Zheng T, Rothman N, et al. Cytokine polymorphisms in the Th1/Th 2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 2006; 107: 4101-4108.
12. Wang SS, Cozen W, Cerhan JR, et al. Immune mechanisms in non-Hodgkin lymphoma: Joint effects of the TNF G308A and IL10 T3575A polymorphisms with non-Hodgkin lymphoma risk factors. Cancer Res 2007; 67: 5042-5054.
13. Lech-Maranda E, Baseggio L, Bienvenu J, et al. Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood 2004; 103: 3529-3534.
14. Bogunia-Kubik K, Mazur G, Wrobel T, et al. Interleukin-10 gene polymorphisms influence the clinical course of non-Hodgkin's lymphoma. Tissue Antigens 2008; 71: 146-150.
15. Warzocha K, Ribeiro P, Bienvenu J, et al. Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin' s lymphoma outcome. Blood 1998; 91: 3574-3581.
16. Juszczynski P, Kalinka E, Bienvenu J, et al. Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome. Blood 2002; 100: 3037-3040.
17. Habermann TM, Wang SS, Maurer MJ, et al. Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era. Blood 2008; 112: 2694-2702.
18. Lech-Maranda E, Bienvenu J, Broussais-Guillaumot F, et al. Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-cell lymphoma in different risk groups defined by the International Prognostic Index. Arch Immunol Ther Exp (Warsz ) 2010; 58: 131-141.
19. Jagadeesh D, Woda BA, Draper J, et al. Post transplant lymphoproliferative disorders: Risk, classification, and therapeutic recommendations. Curr Treat Options Oncol 2012; 13: 122-136.
20. Grogg KL, Miller RF, Dogan A. HIV infection and lymphoma. J Clin Pathol 2007; 60: 1365-1372.
21. van de Schans SA, van Spronsen DJ, Hooijkaas H, et al. Excess of autoimmune and chronic infl ammatory disorders in patients with lymphoma compared with all cancer patients: A cancer registrybased analysis in the south of the Netherlands. Autoimmun Rev 2011; 10: 228-234.
22. Kurzrock R. Cytokine deregulation in hematological malignancies: Clinical and biological implications. Clin Cancer Res 1997; 3: 2581-2584.
23. Mantovani A, Allavena P, Sica A, et al. Cancer-related infl ammation. Nature 2008; 454: 436-444.
24. Bassig BA, Lan Q, Rothman N, et al. Current understanding of lifestyle and environmental factors and risk of non-Hodgkin lymphoma: An epidemiological update. J Cancer Epidemiol 2012; 2012: 978930.
25. Kramer S, Hikel SM, Adams K, et al. Current status of the epidemiologic evidence linking polychlorinated biphenyls and non-Hodgkin lymphoma, and the role of immune dysregulation. Environ Health Perspect 2012; 120: 1067-1075.
26. Ribrag V, Koscielny S, Casasnovas O, et al. Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis. Blood 2009; 113: 3307-3313.
27. Hohaus S, Massini G, D'Alo'F et al. Association between glutathione S-transferase genotypes and Hodgkin's lymphoma risk and prognosis. Clin Cancer Res 2003; 9: 3435-3440.
28. Hohaus S, DiRuscio A, D i Febo A, et al. Glutathione S-transferase P1 genotype and prognosis in Hodgkin's lymphoma. Clin Cancer Res 2005; 11: 2175-2179.
29. Rossi D, Rasi S, Franceschetti S, et al. A nalysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. Leukemia 2009; 23: 1118-1126.
30. Pohlen M, Gerth HU, Liersch R, et al. Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in Burkitt's and primary mediastinal large B-cell lymphoma. Am J Hematol 2011; 86: E61-E64.
31. Holte H, Lepp AS, Bjorkholm M, et al. R-CHOEP-14 x 6 followed by systemic CNS prophylaxis for diffuse large B-cell lymphoma/follicular lymphoma grade 3 with age adjusted IPI score 2-3: Final results of a Nordic Lymphoma Group phase 2 study including 156 patients aged 18-65 years. Blood 2010; 116(Suppl. 1): Abstract 2805.
32. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 2000; 132: 365-386.
33. Ekstrom PO, Bjorheim J, Gaudernack G, et al. Population screening of single-nucleotide polymorphisms exemplified by analysis of 8000 alleles. J Biomol Screen 2002; 7: 501-506.
34. Guldberg P, Gronbak K, Aggerholm A, et al. Detection of mutations in GC-rich DNA by bisulphite denaturing gradient gel electrophoresis. Nucleic Acids Res 1998; 26: 1548-1549.
35. Skibola CF, Curry JD, Nieters A. Genetic susceptibility to lymphoma. Haematologica 2007; 92: 960-969.
36. Chiu BC, Kolar C, Gapstur SM, et al. Association of NAT and GST polymorphisms with non-Hodgkin's lymphoma: A population-based case-control study. Br J Haematol 2005; 128: 610-615.
37. Abdel Rahman HA, Khorshied MM, Elazzamy HH, et al. The link between genetic polymorphism of glutathione-S-transferases, GSTM1, and GSTT1 and diffuse large B-cell lymphoma in Egypt. J Cancer Res Clin Oncol 2012; 138: 1363-1368.
38. A l-Dayel F, A l-Rasheed M, Ibrahim M, et al. Polymorphisms of drug-metabolizing enzymes CYP1A1, GSTT and GSTP contribute to the development of diffuse large B-cell lymphoma risk in the Saudi Arabian population. Leuk Lymphoma 2008; 49: 122-129.
39. Reiner A, Yekutieli D, Benjamini Y. Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 2003; 19: 368-375.
40. Warzocha K, Bienvenu J, Ribeiro P, et al. Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients. Br J Cancer 1998; 77: 2357-2362.
41. Coiffier B. Rituximab therapy in malignant lymphoma. Oncogene 2007; 26: 3603-3613.
42. Iqbal J, Meyer PN, Smith LM, et al. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab. Clin Cancer Res 2011; 17: 7785-7795.
43. Nyman H, Jerkeman M, Karjalainen-Lindsberg ML, et al. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas. Eur J Haematol 2009; 82: 364-372.
44. Stevenson FK, Stevenson GT. Follicular lymphoma and the immune system: From pathogenesis to antibody therapy. Blood 2012; 119: 3659-3667.
45. Alas S, Emmanouilides C, Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 2001; 7: 709-723.
46. Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic d rugs. Cancer Res 2001; 61: 5137-5144.
47. Wilson AG, Symons JA, McDowell TL, et al. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997; 94: 3195-3199.
48. Wanidworanun C, Strober W. Predominant role of tumor necrosis factor-alpha in human monocyte IL-10 synthesis. J Immunol 1993; 151: 6853-6861.
49. Sweeney C, Nazar-Stewart V, Stapleton PL, et al. Glutathione S-transferase M1, T1, and P1 polymorphisms and survival among lung cancer patients. Cancer Epidemiol Biomarkers Prev 2003; 12: 527-533.
50. Goto I, Yoneda S, Yamamoto M, et al. Prognostic significance of germ line polymorphisms of the CYP1A1 and glutathione S-transferase genes in patients with non-small cell lung cancer. Cancer Res 1996; 56: 3725-3730.
51. Cho HJ, Eom HS, Kim HJ, et al. Glutathione-S-transferase genotypes influence the risk of chemotherapy-related toxicities and prognosis in Korean patients with diffuse large B-cell lymphoma. Cancer Genet.Cytogenet 2010; 198: 40-46.
52. Voso MT, D'Alo'F, Putzulu R, et al. Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia. Blood 2002; 100: 2703-2707.
53. Ambrosone CB, Sweeney C, Coles BF, et al. Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. Cancer Res 2001; 61: 7130-7135.